Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oxytocin Response to Oral Estrogen in Arginine Vasopressin Deficiency
NCT06460948Phase 1Completed
- Start
- Nov 2024
- Primary completion
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of norethindrone + ethinyl estradiol in arginine vasopressin deficiency (CDI) and Oxytocin deficiency (2 arms). Primary endpoint: Change in peripheral oxytocin concentration at 24 hours. Started Nov 2024; status: completed.
02
Drugs
norethindrone + ethinyl estradiol
03
Conditions
arginine vasopressin deficiency (CDI)Oxytocin deficiency
Beyond the preview
Go deeper on NCT06460948.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06460948.